Foreign-Trade Zone 7 - Mayaguez, Puerto Rico, Application for Subzone, Amgen Manufacturing Limited, (Biotechnology and Healthcare Products), Juncos, Puerto Rico, 36298 [E8-14537]
Download as PDF
<![CDATA[
36298
Federal Register / Vol. 73, No. 124 / Thursday, June 26, 2008 / Notices
rfrederick on PROD1PC67 with NOTICES
recovery following heavy, chronic
infestations. While public forest
managers have alternative protection
measures available, implementation of
these protection measures is costly and
the economic benefits of protecting
hemlock health are largely unknown.
Eastern hemlock forests provide a
suite of public and private goods that
have economic value, including wildlife
habitat, aesthetic landscapes, and
commercial timber. In addition,
hemlock forests located on public land
provide unique natural settings for
recreational activities, provide habitat
for many species of wildlife, and help
prevent soil erosion along the banks of
streams and rivers. As the impacts of
this invasion accrue, forest managers’
demand for information increases.
Forest Service and university
researchers will collect and analyze
information regarding the value of the
ecosystem services provided by
hemlock forests located on public land
in the Southern Appalachian Mountains
from residents living within 500 miles
of Asheville, North Carolina. The data
and analyses will provide guidance to
public forest managers regarding the
value of ecosystem services supplied by
hemlock forests on the land that they
manage and the level of public support
for alternative hemlock forest-protection
programs.
Telephone interviewers will contact
individual head-of-households via
random digit dialing. Those agreeing to
participate will receive a questionnaire
via the United States Postal Service,
along with a cover letter describing the
purpose of the study, information about
current hemlock forest conditions in
Southern Appalachian Mountain public
forests, and available protection
alternatives. Approximately two weeks
after receiving the questionnaire,
respondents will share answers via
telephone interview.
Estimate of Annual Burden: 45
minutes.
Type of Respondents: Individuals,
heads of households.
Estimated Annual Number of
Respondents: 500.
Estimated Annual Number of
Responses per Respondent: 1.
Estimated Total Annual Burden on
Respondents: 375 hours.
Comment Is Invited
Comment is invited on: (1) Whether
this collection of information is
necessary for the stated purposes and
the proper performance of the functions
of the agency, including whether the
information will have practical or
scientific utility; (2) the accuracy of the
agency’s estimate of the burden of the
VerDate Aug<31>2005
15:05 Jun 25, 2008
Jkt 214001
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including the use of
automated, electronic, mechanical, or
other technological collection
techniques or other forms of information
technology.
All comments received in response to
this notice, including names and
addresses when provided, will be a
matter of public record. Comments will
be summarized and included in the
submission request toward Office of
Management and Budget approval.
Dated: June 23, 2008.
David A. Cleaves,
Associate Deputy Chief, Research and
Development.
[FR Doc. E8–14552 Filed 6–25–08; 8:45 am]
BILLING CODE 3410–11–P
DEPARTMENT OF COMMERCE
Foreign–Trade Zones Board
(Docket 41–2008)
Foreign–Trade Zone 7 – Mayaguez,
Puerto Rico, Application for Subzone,
Amgen Manufacturing Limited,
(Biotechnology and Healthcare
Products), Juncos, Puerto Rico
An application has been submitted to
the Foreign–Trade Zones Board (the
Board) by the Puerto Rico Industrial
Development Company, grantee of FTZ
7, requesting special–purpose subzone
status for the manufacture of
biotechnology and healthcare products
at the facility of Amgen Manufacturing
Limited (Amgen), located in Juncos,
Puerto Rico. The application was
submitted pursuant to the provisions of
the Foreign–Trade Zones Act, as
amended (19 U.S.C. 81a–81u), and the
regulations of the Board (15 CFR part
400). It was formally filed on June 19,
2008.
The Amgen facility (2,000 employees,
28 buildings with 1,900,718 square feet
on 221 acres) is located at Road PR 31
Km. 24.6, in Juncos, Puerto Rico. The
facility will be used to manufacture,
test, package and warehouse Epogen,
(Epoetin Alfa), Neupogen (Filgrastim),
Aransep (Darbepoetin Alfa), Enbrel
(Etanercept), Kineret (Anakinra), and
Neulasta (Pegfilgrastim) (duty–free).
Components and materials sourced from
abroad (representing 2% of the value of
the finished product) include: vials,
syringes, stoppers, plunger rods,
PO 00000
Frm 00004
Fmt 4703
Sfmt 4703
partitions and dispenser packs (HTSUS
duty rate ranges from duty–free to
2.7%).
FTZ procedures would exempt
Amgen from customs duty payments on
the foreign components used in export
production. The company anticipates
that some 48 percent of the plant’s
shipments will be exported. On its
domestic sales, Amgen could choose the
duty–free rate during customs entry
procedures that applies to finished
biotechnology and healthcare products
for the foreign inputs noted above. The
request indicates that the savings from
FTZ procedures would help improve
the plant’s international
competitiveness.
In accordance with the Board’s
regulations, Elizabeth Whiteman of the
FTZ staff is designated examiner to
investigate the application and report to
the Board.
Public comment is invited from
interested parties. Submissions (original
and 3 copies) shall be addressed to the
Board’s Executive Secretary at the
address below. The closing period for
their receipt is August 25, 2008.
Rebuttal comments in response to
material submitted during the foregoing
period may be submitted during the
subsequent 15–day period to September
9, 2008.
A copy of the application and
accompanying exhibits will be available
for public inspection at each of the
following locations:
U.S. Department of Commerce Export
Assistance Center, Tower II Suite 702,
Road 165, Guaynabo, Puerto Rico 00968.
Office of the Executive Secretary,
Foreign–Trade Zones Board, U.S.
Department of Commerce, Room 2111,
1401 Constitution Ave. NW,
Washington, DC 20230.
For further information, contact
Elizabeth Whiteman at
ElizabethlWhiteman@ita.doc.gov or
(202) 482–0473.
Dated: June 19, 2008.
Andrew McGilvray,
Executive Secretary.
[FR Doc. E8–14537 Filed 6–25–08; 8:45 am]
BILLING CODE 3510–DS–S
DEPARTMENT OF COMMERCE
Bureau of Industry and Security
Emerging Technology and Research
Advisory Committee; Notice of
Recruitment of Private-Sector
Members Date Extension
The Bureau of Industry and Security
(BIS) is announcing the creation of and
recruiting individuals for a technical
E:\FR\FM\26JNN1.SGM
26JNN1
]]>Agencies
[Federal Register Volume 73, Number 124 (Thursday, June 26, 2008)]
[Notices]
[Page 36298]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-14537]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
(Docket 41-2008)
Foreign-Trade Zone 7 - Mayaguez, Puerto Rico, Application for
Subzone, Amgen Manufacturing Limited, (Biotechnology and Healthcare
Products), Juncos, Puerto Rico
An application has been submitted to the Foreign-Trade Zones Board
(the Board) by the Puerto Rico Industrial Development Company, grantee
of FTZ 7, requesting special-purpose subzone status for the manufacture
of biotechnology and healthcare products at the facility of Amgen
Manufacturing Limited (Amgen), located in Juncos, Puerto Rico. The
application was submitted pursuant to the provisions of the Foreign-
Trade Zones Act, as amended (19 U.S.C. 81a-81u), and the regulations of
the Board (15 CFR part 400). It was formally filed on June 19, 2008.
The Amgen facility (2,000 employees, 28 buildings with 1,900,718
square feet on 221 acres) is located at Road PR 31 Km. 24.6, in Juncos,
Puerto Rico. The facility will be used to manufacture, test, package
and warehouse Epogen[reg], (Epoetin Alfa), Neupogen[reg] (Filgrastim),
Aransep[reg] (Darbepoetin Alfa), Enbrel[reg] (Etanercept), Kineret[reg]
(Anakinra), and Neulasta[reg] (Pegfilgrastim) (duty-free). Components
and materials sourced from abroad (representing 2[percnt] of the value
of the finished product) include: vials, syringes, stoppers, plunger
rods, partitions and dispenser packs (HTSUS duty rate ranges from duty-
free to 2.7[percnt]).
FTZ procedures would exempt Amgen from customs duty payments on the
foreign components used in export production. The company anticipates
that some 48 percent of the plant's shipments will be exported. On its
domestic sales, Amgen could choose the duty-free rate during customs
entry procedures that applies to finished biotechnology and healthcare
products for the foreign inputs noted above. The request indicates that
the savings from FTZ procedures would help improve the plant's
international competitiveness.
In accordance with the Board's regulations, Elizabeth Whiteman of
the FTZ staff is designated examiner to investigate the application and
report to the Board.
Public comment is invited from interested parties. Submissions
(original and 3 copies) shall be addressed to the Board's Executive
Secretary at the address below. The closing period for their receipt is
August 25, 2008. Rebuttal comments in response to material submitted
during the foregoing period may be submitted during the subsequent 15-
day period to September 9, 2008.
A copy of the application and accompanying exhibits will be
available for public inspection at each of the following locations:
U.S. Department of Commerce Export Assistance Center, Tower II Suite
702, Road 165, Guaynabo, Puerto Rico 00968.
Office of the Executive Secretary, Foreign-Trade Zones Board, U.S.
Department of Commerce, Room 2111, 1401 Constitution Ave. NW,
Washington, DC 20230.
For further information, contact Elizabeth Whiteman at Elizabeth_
Whiteman@ita.doc.gov or (202) 482-0473.
Dated: June 19, 2008.
Andrew McGilvray,
Executive Secretary.
[FR Doc. E8-14537 Filed 6-25-08; 8:45 am]
BILLING CODE 3510-DS-S
